OQROGet OQRO Pro
Insider trade

Keros Therapeutics (KROS)10% owner sold ~$2.76M

Pontifax Management 4 G.P. (2015) Ltd., 10% owner at Keros Therapeutics, sold ~$2.76M of Keros Therapeutics shares.

~$2.76M
Approx. value · 155K sh @ $17.75
Traded
Oct 15, 2025
Filed
Oct 17, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 15, 2025 · this disclosureInsider10% owner sold ~$2.76M of KROS shares in the open market

What came next

  1. Oct 15, 2025Company filing · Form 8-K · Material agreement, ResultsChanged a top executive or board member, and signed an important agreement (and 3 more items)“In accordance with the terms of the Pontifax Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum have resigned from their respective positions as a member of the Company’s board of directors and all committees thereof, effective as of October 15, 2025.”
  2. Oct 15, 2025Insider · 2 peopleInsiders: 6 sales (~$177.9M)
  3. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Keros Therapeutics

For Keros Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KROS page.

Other recent filings by Pontifax Management 4 G.P. (2015) Ltd., 10% owner

The full history of Pontifax Management 4 G.P. (2015) Ltd., 10% owner is on the profile page.

How this filing works

Other disclosures at Keros Therapeutics

Everything OQRO holds on this company is on its KROS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data